Welcome to our dedicated page for IMMUNIC SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and expire on March 27, 2036.
The Board conditionally approved the grant on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the June 29, 2026 annual meeting. The option was fully vested as of March 27, 2026, and Rudick now holds options for 25,370 shares directly.
IMMUNIC, INC. director Tamar D. Howson received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share, are fully vested as of March 27, 2026, and expire on March 27, 2036. The grant was conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the company’s 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders held on June 29, 2026.
IMMUNIC, INC. director Joerg Neermann reported a grant of stock options on common stock. He received options on 25,370 shares at an exercise price of $10.90 per share, all of which are fully vested as of March 27, 2026.
The options were conditionally approved by the board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. That approval was obtained at the 2026 Annual Meeting of Stockholders on June 29, 2026. Following the grant, this option position totals 25,370 shares and there are no remaining derivative holdings shown beyond this grant.
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the Board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this award, Phillips holds options on 25,370 shares directly.
IMMUNIC, INC. reported that President and COO Jason Tardio received a grant of stock options covering 253,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The grant was conditionally approved by the board and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, aligning the executive’s compensation with longer-term company performance.
IMMUNIC, INC. Chief Financial Officer Glenn Whaley received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The award was approved in connection with an amendment to the company’s 2019 Omnibus Equity Incentive Plan that stockholders approved at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The underlying shares vest 25% on April 2, 2027, with the remaining portion vesting in equal monthly installments over the next 36 months. Following this grant, Whaley holds 120,000 options directly.
IMMUNIC, INC. director Daniel Vitt received a grant of stock options covering 445,000 shares of common stock as equity compensation. The options have an exercise price of $11.60 per share and expire on April 2, 2036, with all 445,000 options shown as held directly after the grant.
The grant was conditionally approved by the Board of Directors and became effective only after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following thirty-six months, tying director compensation to longer-term company performance.
IMMUNIC, INC. director Michael W. Bonney received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $12.0800 per share and expire on May 15, 2036. They vest in thirty-six equal monthly installments starting on May 15, 2026, providing gradual future ownership potential if exercised. Following this grant, the filing shows Bonney holding options for 100,000 underlying shares.
Immunic, Inc. reported results from its annual stockholder meeting. Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing shares authorized for issuance under the plan by 6,000,000 to a total of 8,644,887 common shares. This expands the pool available for employee and director equity awards.
Three Class III directors – Michael Bonney, Thorvald Nagel and Richard Rudick – were elected to serve until the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
IMMUNIC, INC. granted its Chief Executive Officer, Erik Lundgren, stock options covering 1,000,000 shares of common stock. The options have an exercise price of $13.05 per share and expire on May 22, 2036. They are time-vested: 25% vest on May 22, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued employment.